FDA Grants Priority Review for Alexion's sBLA for Soliris as a Treatment for Patients with Atypical Hemolytic Uremic Syndrome

Alexion Pharmaceuticals, Inc. ALXN announced today that the U.S. Food and Drug Administration has granted the Company's request for Priority Review of its supplemental Biologics License Application for Soliris as a treatment for patients with atypical Hemolytic Uremic Syndrome. A Priority Review designation is given to drugs that may offer major advances in treatment, or provide a treatment where no adequate therapy exists.